Different Incidence of Venous Thrombosis in Patients with Inherited Deficiencies of Antithrombin III, Protein C and Protein S

Summary

A cohort study was undertaken to compare the incidence of thrombosis in patients with inherited deficiency of Antithrombin III (n = 9), Protein C (n = 36) and Protein S (n = 36). The patients were stratified for schedule of antithrombotic prophylaxis and followed for a total period of 160 patient-years. Seven venous thrombosis were observed for a total incidence of 4.3% pts.-ys. The incidence of thrombosis was not significantly different in patients of different age, sex and schedule of prophylaxis, although there was a trend to a lower incidence in young individuals and in those receiving long-term oral anticoagulation. Patients with AT III deficiency had an higher incidence of thrombosis than patients with Protein C or Protein S deficiency (12 vs. 2.8 vs. 3.3% pts.-ys., p <0.05), despite the fact that they were, on average, younger and more prophylaxed. This study suggests that congenital Antithrombin III deficiency constitutes a greater risk of thrombosis than congenital deficiences of Protein C and Protein S.

• References

• 1 The British Committee for Standards in Haematology. Guidelines on the investigation and management of thrombophilia. J Clin Pathol 1990; 43: 703-9
• 2 Greaves M, Preston FE. The hypercoagulable state in clinical practice. Br J Haematol 1991; 79: 148-51
• 3 Walker ID. Management of thrombophilia in pregnancy. Blood Reviews 1991; 5: 227-33
• 4 Hull RD, Delmore TJ, Genton E, Hirsh J, Gent M, Sackett D, Mc Loughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-8
• 5 Hull RD, Delmore TJ, Carter C, Hirsh J, Genton E, Gent M, Turpie G, McLaughlin D. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94
• 6 Davidson JF, Colvin BT, Barrowcliffe TW, Kernoff PB A, Machin SJ, Poller L, Preston FE, Walker ID. Guidelines on oral anticoagulation: second edition. J Clin Pathol 1990; 43: 177-83
• 7 Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1989; 95 (Supplement) 37-51
• 8 Tripodi A. Mannucci PM and the ad hoc study group. A survey of inherited thrombotic syndromes in Italy. Res Clin Lab 1989; 19: 67-74
• 9 Ben Tal O, Zivelin A, Scligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemostas 1989; 61: 50-4
• 10 Conard J, Horcllou MH, Van Dreden P, Lecompte X, Samama M. Thrombosis and pregnancy in congenital deficiencies of AT III, Protein C or Protein S: study of 78 women. Thromb Haemostas 1990; 63: 319-20
• 11 Tabernero MD, Tomas JF, Alberca I, Orfao A, Borrasca AL, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-54
• 12 Hirsh J, Piovella F, Pini M. Congenital Antithrombin III deficiency. Am J Med 1989; 87 Suppl. 3B 345-85
• 13 Broekmans AW. Hereditary Protein C deficiency. Haemostasis 15: 233-40
• 14 Engesser L, Broekmans AW, Briet E, Brommer EJ P, Bertina RM. Hereditary Protein S deficiency: clinical manifestations. Ann Int Med 1987; 106: 677-82
• 15 Odegard OR, Lie M, Abildgaard U. Heparin cofactor activity measured with an amidolytic assay. Thromb Res 1975; 6: 287-94
• 16 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Internat J Immunochemistry 1965; 2: 235-54
• 17 Martinoli JL, Stocker K. Fast functional protein C assay using Protac, a novel Protein C activator. Thromb Res 1986; 43: 253-64
• 18 Finazzi G, Viero P, Cortelazzo S, Barbui T. Hereditary dysfunctional Protein C (Protein C ‘Bergamo II’) diagnosed by a rapid assay. Haematologica 1987; 72: 375-84
• 19 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Analytical Biochemistry 1966; 15: 45-52
• 20 Preda L, Tripodi A, Valsecchi C, Lombardi A, Finotto E, Mannucci PM. A prothrombin time-based functional assay of Protein S. Thromb Res 1990; 60: 19-32
• 21 Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986; 67: 504-8
• 22 Chesebro JH, Fuster V, Elvebach LR, Mc Goon DC, Pluth JR, Puga FJ. et al Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51: 1537-41
• 23 Dale J, Myhre E, Loew D. Bleeding during acetylsalicyhc acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J 1980; 99: 746-51
• 24 Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant therapy. Chest 1992; 102 (Supplement) 352-63
• 25 Cortelazzo S, Finazzi G, Viero P, Galli M, Remuzzi A, Parenzan L, Barbui T. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemostas 1993; 69: 316-20
• 26 Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemostas 1992; 68: 1-6
• 27 Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in Antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Int Med 1992; 116: 754-61
• 28 Rosendaal FR, Heijboer H, Briet E, Buller HR, Brandjes DP M, De Bruin K, Hommes DW, Vandenbroucke JP. Mortality in hereditary antithrombin-III deficiency-1830 to 1989. Lancet 1991; 337: 260-2
• 29 De Stefano V, Leone G. Mortality related to thrombosis in congenital antithrombin III deficiency. Lancet 1991; 337: 847-8